Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Blood (2024) 143 (16): 1616–1627.

https://doi.org/10.1182/blood.2023021959

Published: 2024

Includes: Supplemental data

Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller

Blood (2022) 140 (Supplement 1): 7016–7017.

https://doi.org/10.1182/blood-2022-163753

Published: 2022

Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Blood (2021) 138 (Supplement 1): 639.

https://doi.org/10.1182/blood-2021-153146

Published: 2021

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Blood (2018) 132 (Supplement 1): 6.

https://doi.org/10.1182/blood-2018-99-116653

Published: 2018

Journal Articles

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Christian Thiede, MD, Thomas W Prior, MD, Serena Lavorgna, PhD, Jürgen Krauter, MD, Eva Barragán, Josep Nomdedeu, MD PhD, Joop H. Jansen, Andrew H Wei, MBBS, PhD, Weiqiang Zhao, MD PhD, Xiaohong Li, Celine Pallaud, PhD, Eva Tiecke, PhD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard M. Stone, MD, Konstanze Döhner, MD

Blood (2018) 132 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2018-99-112127

Published: 2018

Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2018-99-110847

Published: 2018

Journal Articles

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Dan Jones, MD PhD, Huolin Tu, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Xiaokang Pan, PhD, Susan Long, Brianna Sisson, Sean Caruthers, Peng Ru, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Lynne V. Abruzzo, MD PhD, Weiqiang Zhao, MD PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2018-99-116293

Published: 2018

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Leslie A. Andritsos, MD, Mirela Anghelina, MD, Nicole R. Grieselhuber, MD PhD, Sameek Roychowdhury, MD PhD, Julie Reeser, PhD, Cynthia Timmers, PhD, Aharon G. Freud, MD PhD, James S. Blachly, MD, David M. Lucas, PhD, Gerard Lozanski, MD, Jeffrey Jones, MD MPH, Kerry A. Rogers, MD, Weiqiang Zhao, MD PhD, Michael R. Grever, MD

Blood (2016) 128 (22): 5598.

https://doi.org/10.1182/blood.V128.22.5598.5598

Published: 2016

Journal Articles

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3 -ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

Geoffrey L. Uy, MD, Sumithra Mandrekar, PhD, Kristina Laumann, Ben Sanford, Guido Marcucci, MD, Weiqiang Zhao, MD PhD, Mark J. Levis, MD PhD, Heidi D. Klepin, MD MS, Maria R. Baer, MD, Bayard L. Powell, MD, Peter Westervelt, MD PhD, Daniel J. DeAngelo, MD PhD, Wendy Stock, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2015) 126 (23): 319.

https://doi.org/10.1182/blood.V126.23.319.319

Published: 2015

Journal Articles

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O'Brien

Blood (2015) 125 (16): 2497–2506.

https://doi.org/10.1182/blood-2014-10-606038

Published: 2015

Includes: Supplemental data

Journal Articles

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Guido Marcucci, MD, Susan Geyer, PhD, Weiqiang Zhao, MD PhD, Andrew J Caroll, PhD, Donna Bucci, Geoffrey L. Uy, MD, William Blum, MD, Timothy Pardee, MD PhD, Meir Wetzler, MD, Wendy Stock, MD, Jonathan E. Kolitz, MD, Ann-Kathrin Eisfeld, MD, Clara D. Bloomfield, MD, Richard M. Stone, MD, Richard A. Larson

Blood (2014) 124 (21): 8.

https://doi.org/10.1182/blood.V124.21.8.8

Published: 2014

Journal Articles

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

Blood (2014) 124 (1): 42–48.

https://doi.org/10.1182/blood-2014-02-555722

Published: 2014

Includes: Supplemental data

Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood (2014) 123 (12): 1810–1817.

https://doi.org/10.1182/blood-2013-09-527853

Published: 2014

Includes: Supplemental data

Journal Articles

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Geoffrey L. Uy, MD, Ben Sanford, Guido Marcucci, MD, Weiqiang Zhao, MD, PhD, Susan Geyer, PhD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD, Maria R. Baer, MD, Wendy Stock, M.D., Richard M. Stone, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 2653.

https://doi.org/10.1182/blood.V122.21.2653.2653

Published: 2013

Journal Articles

Hemophagocytosis in a patient with persistent chronic lymphocytic leukemia

Elham Kamangar, Weiqiang Zhao

Blood (2013) 122 (13): 2149.

https://doi.org/10.1182/blood-2013-04-493072

Published: 2013

NARROW

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3 -ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Hemophagocytosis in a patient with persistent chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only